NCT05190744 - Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions

Autosomal Dominant Polycystic Kidney DiseaseNephrogenic Diabetes InsipidusAcquired Nephrogenic Diabetes InsipidusCongenital Nephrogenic Diabetes Insipidus

Interventions

DRUG

1000mg twice daily (BID). The dose of PB inducing the maximal increase in urine osmolality will be continued for up to four weeks providing that no side effects are observed including clinical and laboratory surveillance.

Trial Locations (1)

32224

RECRUITING

Mayo Clinic, Jacksonville